Press release
26-11-2026

Genetic Analysis AS: Publication of interim report Q3 2026

OSLO, NORWAY - November 26, 2026: Genetic Analysis AS ("GA" or the "Company") hereby publishes the interim report for Q3, and January - September 2026. The report is available as an attached file to this release and on the Company's website. Below is a summary of the report.

Ronny Hermansen, CEO of Genetic Analysis, comments:
"The third quarter of 2026 marked strong execution and strategic progress for Genetic Analysis. We delivered substantial growth in our core business, expanded the global reach of the GA-map® platform, strengthened our scientific position and advanced our ambition to build a scalable business driven by recurring reagent revenues."

(NOK thousand)	Q3 2026	Q3 2025	9M 2026	9M 2025	FY 2025
Sales revenue	3,116	2,073	12,250	10,360	16,712
Other income	701	1,102	1,898	3,981	4,460
Operating income	3,817	3,175	14,149	14,341	21,172
Cost of goods sold	743	747	2,241	2,690	4,700
Gross profit	2,372	1,326	10,009	7,669	12,012
Operating expenses (ex. depr. & amort.)	3,873	4,265	16,898	16,102	22,563
EBITDA	-799	-1,838	-4,991	-4,451	-6,091
Net profit/loss	-2,275	-3,279	-9,322	-8,819	-11,413
Earnings per share (NOK)	-0.03	-0.05	-0.13	-0.14	-0.18

(NOK thousand)	2026-09-30	2025-09-30	FY 2025
Total non-current assets	22,602	21,126	21,374
Total current assets	15,479	22,719	31,072
Total equity	18,613	29,540	27,079
Total non-current liabilities	7,893	7,055	6,401
Total current liabilities	11,575	7,250	18,966
Cash and cash equivalents (*)	6,309	17,741	24,029
Equity ratio (%)	49%	67%	52%

* *FY 2025 includes a positive impact from customer pre-payment*.

Definitions:

Equity ratio:	Shareholder's equity as a proportion of total assets.
Earnings per share:	Profit/Loss for the period divided by an average number of shares.
Constant currency:	This year's sales converted to NOK by using last year's exchange rates.

Press release
26-11-2026

Financial Highlights

- Sales revenue (excluding grants) reached NOK 3.116 million in Q3 2026, an increase of 50.3% compared to Q3 2025 (a 63.3% increase at constant currency).
- Key product sales (GA-map® Dysbiosis Test reagent kits) reached NOK 2.925 million in Q3 2026, an increase of 58.7% compared to Q3 2025 (a 72.6% increase at constant currency).
- Gross profit (excluding other income) was NOK 2.372 million in Q3 2026, corresponding to a gross margin of 76.1%, compared to NOK 1.326 million and 63.9% in Q3 2025.
- Cost of goods sold totaled NOK 0.743 million in Q3 2026, compared to NOK 0.747 million in Q3 2025.
- EBITDA in Q3 2026 totaled NOK -0.799 million, compared to NOK -1.838 million in Q3 2025.
- Cash and cash equivalents amounted to NOK 6.309 million on September 30, 2026, compared to NOK 17.741 million on September 30, 2025.

Commercial highlights

- Q3 reagent kit sales grew 72.6% at constant currency compared to Q3 2025.
- 9M reagent kit sales grew 35.6% at constant currency compared to the same period in 2025.
- First Australian placement of the GA-map® Dysbiosis Test at the Centre for Digestive Diseases (CDD) in Sydney, expanding the platform's international presence.

Product and Scientific highlights

- A peer-reviewed study published in Gut Microbes confirmed the consistent performance of the GA-map® Dysbiosis Test across geographically diverse populations, supporting its international applicability.
- Strengthened IP portfolio with a Canadian patent application allowed for grant, covering a diagnostic method to identify IBS patients likely to respond to Faecal Microbiota Transplantation (FMT).
- Filed a new patent application covering the pipeline GA-map® IBD Precision Dx test for ulcerative colitis patient stratification.

Highlights during Q2 2026

- On August 21, Genetic Analysis announced the first Australian placement of the GA-map® Dysbiosis Test at the Centre for Digestive Diseases (CDD) in Sydney, expanding the Company's international presence to Australia alongside the USA, Europe and Asia.

- On September 3, Genetic Analysis announced the appointment of Mira Halvorsen Børstad as Chief Commercial Officer (CCO), strengthening the Company's commercial organization and supporting further international expansion.
- On September 10, Genetic Analysis filed a new patent application covering GA-map® IBD Precision Dx for ulcerative colitis patient stratification, further strengthening the intellectual property protection of its diagnostic pipeline.
- On September 22, Genetic Analysis announced that Canadian patent application no. 3039144 had been allowed for grant. The patent covers a diagnostic method to identify patients with Irritable Bowel Syndrome (IBS) who are more likely to respond to Faecal Microbiota Transplantation (FMT), further strengthening the Company's intellectual property portfolio.

Highlights after the end of the period

- On October 15, Genetic Analysis announced that results from the development of GA-map® IBD Precision Dx had been selected for oral presentation at UEG Week 2026 in Barcelona. The research demonstrates the potential of microbiome-based testing to identify ulcerative colitis patients at increased risk of an aggressive disease course, supporting earlier patient stratification and more personalized treatment decisions.
- On November 25, Genetic Analysis announced an Original Equipment Manufacturer (OEM) agreement with EMD Millipore Corporation, an affiliate of Merck KGaA. The collaboration includes an initial plan to launch three products and aims to broaden the commercial reach of GA-map® technology within the global research and life science market, supporting the Company's strategy for international expansion and long-term commercial growth.

For further information, please contact:
Ronny Hermansen, CEO
E-mail: rh@genetic-analysis.com

This disclosure contains information that Genetic Analysis AS is obliged to make public pursuant to the EU Market Abuse Regulation (EU nr 596/2014). The information was submitted for publication, through the agency of the contact person, at the time indicated by Genetic Analysis AS news distributor upon publication of this press release.

About Genetic Analysis:

Genetic Analysis AS (GA) is a molecular diagnostics company focused on developing targeted microbiome-based solutions using its proprietary GA-map® platform. With more than 15 years of experience in microbiome research and product development, the company works across disease areas including IBS, IBD, and recurrent Clostridioides difficile infection. GA-map® enables standardized and reproducible profiling of clinically relevant microbial patterns, supporting both research and diagnostic applications. GA has a highly qualified team with expertise in molecular biology, bioinformatics, bioengineering, operations, and sales.
For more information, visit www.genetic-analysis.com

Interested in reading more about GA's products? Please visit ga-map.com
Stay updated on GA and sign up for more investor-related information:

Press release
26-11-2026

https://www.genetic-analysis.com/subscriptions/